Scribe Therapeutics Inc.
SCTXHealthcare|Biotechnology|US
$15.70
+0.22 (+1.42%)
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07428473 A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) | Elevated LDL-C and High Cholesterol | P1 | Recruiting | 64 | Open-label | STX-1150 |